The main risk stack is straightforward: first-
fab throughput must keep up, the lead customer must transition to Gen 5 on time, and second-
fab capacity has to arrive before customers push harder for second sources. On top of that, licensing upside is valuable but not yet fully proven as recurring, and the stock’s current premium means even decent execution may not translate into outsized shareholder returns.